{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:46:48Z","timestamp":1794692808729,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2024ZDXK0043"],"award-info":[{"award-number":["2024ZDXK0043"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473185"],"award-info":[{"award-number":["82473185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202922"],"award-info":[{"award-number":["82202922"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gendis.2025.101732","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T02:03:29Z","timestamp":1750644209000},"page":"101732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Xuehui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-1562","authenticated-orcid":false,"given":"Yanting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-2504","authenticated-orcid":false,"given":"Fuwen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gendis.2025.101732_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.gendis.2025.101732_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2025.101732_bib3","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/jco.2015.33.15_suppl.5003","volume":"33","author":"Small","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Pt 3","key":"10.1016\/j.gendis.2025.101732_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","article-title":"Molecular mechanisms underlying the development of neuroendocrine prostate cancer","volume":"86","author":"Liu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.gendis.2025.101732_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101732_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"30","key":"10.1016\/j.gendis.2025.101732_bib7","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis - a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101732_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"issue":"6577","key":"10.1016\/j.gendis.2025.101732_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"CDK4 and CDK6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science."},{"issue":"5293","key":"10.1016\/j.gendis.2025.101732_bib10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.gendis.2025.101732_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.gendis.2025.101732_bib12","doi-asserted-by":"crossref","first-page":"17873","DOI":"10.18632\/oncotarget.4286","article-title":"RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy","volume":"6","author":"Indovina","year":"2015","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.gendis.2025.101732_bib13","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1158\/0008-5472.CAN-08-0121","article-title":"A small-molecule E2F inhibitor blocks growth in a melanoma culture model","volume":"68","author":"Ma","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2025.101732_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcancer.2023.03.004","article-title":"Role of E2F transcription factor in oral cancer: recent insight and advancements","volume":"92","author":"Kassab","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.gendis.2025.101732_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-0716-3441-7_2","article-title":"Virtual screening process: a guide in modern drug designing","volume":"2714","author":"Panwar","year":"2024","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101732_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/17460441.2024.2390511","article-title":"Perspectives on current approaches to virtual screening in drug discovery","volume":"19","author":"Muegge","year":"2024","journal-title":"Expet Opin Drug Discov"},{"issue":"7958","key":"10.1016\/j.gendis.2025.101732_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.gendis.2025.101732_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.apsb.2023.11.021","article-title":"Late-stage modification of bioactive compounds: improving druggability through efficient molecular editing","volume":"14","author":"Huo","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.gendis.2025.101732_bib19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/ph15050646","article-title":"Drug design by pharmacophore and virtual screening approach","volume":"15","author":"Giordano","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.gendis.2025.101732_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116333","article-title":"Qingdai decoction suppresses prostate cancer growth in lethal-stage prostate cancer models","volume":"308","author":"Chen","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.gendis.2025.101732_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107731","article-title":"Reynoutria multiflora (Thunb.) Moldenke and its ingredient suppress lethal prostate cancer growth by inducing CDC25B-CDK1 mediated cell cycle arrest","volume":"152","author":"Zhou","year":"2024","journal-title":"Bioorg Chem"},{"issue":"19","key":"10.1016\/j.gendis.2025.101732_bib22","doi-asserted-by":"crossref","first-page":"10104","DOI":"10.1093\/nar\/gkz790","article-title":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.101732_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.gendis.2025.101732_bib24","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"34","key":"10.1016\/j.gendis.2025.101732_bib25","doi-asserted-by":"crossref","first-page":"13576","DOI":"10.1039\/D4SC02512A","article-title":"The efficient synthesis of three-membered rings via photo- and electrochemical strategies","volume":"15","author":"Han","year":"2024","journal-title":"Chem Sci"},{"issue":"8","key":"10.1016\/j.gendis.2025.101732_bib26","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1039\/D3GC04431A","article-title":"A visible-light-promoted metal-free approach for N\u2013H insertions by using donor\/donor diazo precursors","volume":"26","author":"Zhang","year":"2024","journal-title":"Green Chem"},{"issue":"5","key":"10.1016\/j.gendis.2025.101732_bib27","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s11426-024-2380-4","article-title":"Catalyst-free photoinduced C(sp3)-C(sp3) bond formation through C-H insertions using non-activated alkanes\/ethers","volume":"68","author":"Li","year":"2025","journal-title":"Sci China Chem"},{"issue":"3","key":"10.1016\/j.gendis.2025.101732_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101732_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40364-024-00702-w","article-title":"Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples","volume":"12","author":"B\u00fcy\u00fccek","year":"2024","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101732_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s43556-021-00053-0","article-title":"Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival","volume":"2","author":"Liu","year":"2021","journal-title":"Mol Biomed"},{"issue":"4","key":"10.1016\/j.gendis.2025.101732_bib31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.humpath.2006.11.007","article-title":"Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas","volume":"38","author":"Sheehan","year":"2007","journal-title":"Hum Pathol"},{"issue":"6320","key":"10.1016\/j.gendis.2025.101732_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.gendis.2025.101732_bib33","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/1878-0261.12706","article-title":"Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer","volume":"14","author":"Mazzu","year":"2020","journal-title":"Mol Oncol"},{"issue":"14","key":"10.1016\/j.gendis.2025.101732_bib34","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1158\/1078-0432.CCR-18-4046","article-title":"A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)","volume":"25","author":"Mazzu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2025.101732_bib35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ebiom.2019.03.032","article-title":"Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of \u03b2-catenin in cancer stem-like cells","volume":"42","author":"Zhang","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gendis.2025.101732_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canlet.2016.10.021","article-title":"Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation","volume":"385","author":"Wu","year":"2017","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.gendis.2025.101732_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101732_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.trecan.2019.03.005","article-title":"Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy","volume":"5","author":"Knudsen","year":"2019","journal-title":"Trends Cancer"},{"issue":"15","key":"10.1016\/j.gendis.2025.101732_bib39","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 loss in cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:20:27Z","timestamp":1778872827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2352304225002211"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101732","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd\u00e9","name":"copyright","label":"Copyright"}],"article-number":"101732"}}